Teva Pharma (TEVA) PT Raised to $14 at BofA Securities following US generics segment review
Tweet Send to a Friend
BofA Securities analyst Jason Gerberry raised the price target on Teva Pharma (NYSE: TEVA) to $14.00 (from $13.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
